Abstract
Anti-amyloid antibodies are moving from clinical trials into patients to treat early clinical stages of Alzheimer’s disease.
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have